Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA 15212, USA.
Department of Mathematics and Statistics, University of New Mexico, Albuquerque, NM 87106, USA.
Viruses. 2023 Apr 5;15(4):922. doi: 10.3390/v15040922.
Acute respiratory distress syndrome (ARDS) is one the leading causes of mortality and morbidity in patients with COVID-19 and Influenza, with only small number of studies comparing these two viral illnesses in the setting of ARDS. Given the pathogenic differences in the two viruses, this study shows trends in national hospitalization and outcomes associated with COVID-19- and Influenza-related ARDS. To evaluate and compare the risk factors and rates of the adverse clinical outcomes in patients with COVID-19 associated ARDS (C-ARDS) relative to Influenza-related ARDS (I-ARDS), we utilized the National Inpatient Sample (NIS) database 2020. Our sample includes 106,720 patients hospitalized with either C-ARDS or I-ARDS between January and December 2020, of which 103,845 (97.3%) had C-ARDS and 2875 (2.7%) had I-ARDS. Propensity-matched analysis demonstrated a significantly higher in-hospital mortality (aOR 3.2, 95% CI 2.5-4.2, < 0.001), longer mean length of stay (18.7 days vs. 14.5 days, < 0.001), higher likelihood of requiring vasopressors (aOR 1.7, 95% CI 2.5-4.2) and invasive mechanical ventilation (IMV) (aOR 1.6, 95% CI 1.3-2.1) in C-ARDS patients. Our study shows that COVID-19-related ARDS patients had a higher rate of complications, including higher in-hospital mortality and a higher need for vasopressors and invasive mechanical ventilation relative to Influenza-related ARDS; however, it also showed an increased utilization of mechanical circulatory support and non-invasive ventilation in Influenza-related ARDS. It emphasizes the need for early detection and management of COVID-19.
急性呼吸窘迫综合征(ARDS)是 COVID-19 和流感患者死亡和发病的主要原因之一,仅有少数研究比较了这两种病毒性疾病在 ARDS 中的情况。鉴于这两种病毒的发病机制不同,本研究显示了与 COVID-19 和流感相关 ARDS 相关的国家住院和结局的趋势。为了评估和比较 COVID-19 相关 ARDS(C-ARDS)与流感相关 ARDS(I-ARDS)患者的不良临床结局的危险因素和发生率,我们利用了 2020 年国家住院患者样本(NIS)数据库。我们的样本包括 2020 年 1 月至 12 月期间因 C-ARDS 或 I-ARDS 住院的 106720 名患者,其中 103845 名(97.3%)患有 C-ARDS,2875 名(2.7%)患有 I-ARDS。倾向匹配分析显示,C-ARDS 患者的院内死亡率(调整优势比[aOR]3.2,95%置信区间[CI]2.5-4.2,<0.001)、平均住院时间(18.7 天 vs. 14.5 天,<0.001)、需要血管加压素(aOR 1.7,95% CI 2.5-4.2)和有创机械通气(IMV)(aOR 1.6,95% CI 1.3-2.1)的可能性更高。我们的研究表明,与流感相关的 ARDS 相比,COVID-19 相关的 ARDS 患者并发症发生率更高,包括院内死亡率更高,需要血管加压素和有创机械通气的可能性更高;然而,它也显示出流感相关 ARDS 中机械循环支持和无创通气的利用率增加。这强调了早期检测和管理 COVID-19 的必要性。